AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35210307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for up to four doses, followed by nivolumab 480 mg every 4 weeks for ≤2 years)
Number of subjects: 52
Study 35210307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 52
Study 35210326 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-high asthma phenotype
Number of subjects: 1125
Study 35210531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS group)
Number of subjects: 1194
Study 35210531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg alteplase within 4.5 h (PCS group)
Number of subjects: 1194
Study 35210531 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.9 mg/kg alteplase within 4.5 h (ACS and PCS groups)
Number of subjects: 1194
Study 35210595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 7215
Study 35210595 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7215
Study 35210606 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-HB27-LNP; administered intravenously; single prophylactic administration.
Number of subjects: 0
Study 35210606 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-HB27-LNP; administered prophylactically in a close contact transmission model.
Number of subjects: 0
Study 35210758 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 3719
Study 35210852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential melphalan-based conditioning therapy
Number of subjects: 173
Study 35210852 — intervention group
Group type: EXPERIMENTAL
Intervention: Blast count >20% prior to conditioning
Number of subjects: 173
Study 35211079 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural history data from 41 patients with longitudinal assessments in the DEM-CHILD DB (NCT04613089)
Number of subjects: 140
Study 35211079 — intervention group
Group type: COMPARATOR
Intervention: Natural history data
Number of subjects: 140
Study 35211079 — intervention group
Group type: COMPARATOR
Intervention: Natural history data accepted by EMA and FDA
Number of subjects: 140
Study 35211080 — intervention group
Group type: EXPERIMENTAL
Intervention: MyoPro™ orthosis used in motor learning-based therapy
Number of subjects: 13
Study 35211494 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition group (n=1258, 60.4% of patients)
Number of subjects: 2083
Study 35211494 — intervention group
Group type: COMPARATOR
Intervention: Non-malnutrition group (n=825, 39.6% of patients)
Number of subjects: 2083
Study 35211494 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition group (age ≤ 75 years)
Number of subjects: 2083
Study 35211494 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished patients with CA-AKI
Number of subjects: 2083
Study 35211517 — intervention group
Group type: EXPERIMENTAL
Intervention: AF catheter ablation (AFCA)
Number of subjects: 1353
Study 35211772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Time ≤ 6 hours
Number of subjects: 2749
Study 35211772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Time 6-12 hours
Number of subjects: 2749
Study 35211772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Time 12-18 hours
Number of subjects: 2749
Study 35211772 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Time 18-24 hours
Number of subjects: 2749
Study 35211772 — intervention group
Group type: COMPARATOR
Intervention: Patients with symptom onset > 24 hours
Number of subjects: 2749
Study 35211773 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision aid for midfacial trauma (facial depression, epistaxis, ocular movement limitation, palpable step-off, objective malocclusion, tooth mobility or avulsion)
Number of subjects: 766
Study 35211773 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision aid for mandibular trauma (mouth opening limitation, jaw movement pain, objective malocclusion, tooth mobility or avulsion)
Number of subjects: 766
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR CKiD (bedside Schwartz equation)
Number of subjects: 600
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR EKFC
Number of subjects: 600
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: modified CKD-EPI40
Number of subjects: 600
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR CKiD under 25 (CKiDU25)
Number of subjects: 600
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR FAS age
Number of subjects: 600
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR FAS height
Number of subjects: 600
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: adjusted-creatinine revised Lund-Malmö (LMR18)
Number of subjects: 600
Study 35211793 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum creatinine (SCr)
Number of subjects: 600
Study 35211796 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]*[IGFBP7] measured using NEPHROCHECK® at eight perioperative time points
Number of subjects: 230
Study 35211796 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary [TIMP-2]*[IGFBP7]
Number of subjects: 230
Study 35211796 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPHROCHECK® test added to postoperative parameters
Number of subjects: 230
Study 35211837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound Perfusion Imaging (UPI)
Number of subjects: 30
Study 35211851 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding until 6 months
Number of subjects: 45
Study 35211851 — intervention group
Group type: EXPERIMENTAL
Intervention: Never breastfed exclusively
Number of subjects: 45
Study 35211851 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of solid foods
Number of subjects: 45
Study 35211851 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaning after the 4th month of age
Number of subjects: 45
Study 35211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in GA/DRF group
Number of subjects: 1057
Study 35211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in IFN/DRF group
Number of subjects: 1057
Study 35211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in DRF-rollover group
Number of subjects: 1057
Study 35211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) in DMF-rollover group
Number of subjects: 1057
Study 35211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) overall
Number of subjects: 1057
Study 35211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) after 2 years
Number of subjects: 1057
Study 35211872 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF) after transition from GA or IFN
Number of subjects: 1057
Study 35212017 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs) during cognitive-behavioral therapy (CBT-E)
Number of subjects: 55
Study 35212017 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT-E) without JITAIs
Number of subjects: 55
Study 35212262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral masseter EMG (2M)
Number of subjects: 10
Study 35212262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral temporalis EMG (2T)
Number of subjects: 10
Study 35212262 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral masseter EMG (1M)
Number of subjects: 10
Study 35212262 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral temporalis EMG (1T)
Number of subjects: 10
Study 35212262 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral chin EMG (1C)
Number of subjects: 10
Study 35212262 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral chin EMG (2C)
Number of subjects: 10
Study 35212262 — intervention group
Group type: COMPARATOR
Intervention: Reference standard (4MT)
Number of subjects: 10
Study 35212260 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 69001
Study 35212470 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment (ART)
Number of subjects: 1363
Study 35212470 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use
Number of subjects: 1363
Study 35212470 — intervention group
Group type: EXPERIMENTAL
Intervention: No drug use and no experience of violence with ART
Number of subjects: 1363
Study 35212470 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 1363
Study 35212470 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience of violence
Number of subjects: 1363
Study 35212470 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate internalized stigma
Number of subjects: 1363
Study 35212470 — intervention group
Group type: COMPARATOR
Intervention: Drug use and experience of violence
Number of subjects: 1363
Study 35212486 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA gene variant c.376A>G (p.Ser126Gly)
Number of subjects: 5
Study 35212486 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examination after 12 years
Number of subjects: 5
Study 35212633 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE intervention delivered via SMS text messaging, including role model videos, mental wellness strategies, and social support, with 3 to 5 messages per week.
Number of subjects: 1030
Study 35212633 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE intervention content (including role model videos)
Number of subjects: 1030
Study 35212633 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAVE intervention
Number of subjects: 1030
Study 35212640 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-promoting intervention for vaccine hesitancy reduction
Number of subjects: 120
Study 35212640 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 120
Study 35212639 — intervention group
Group type: EXPERIMENTAL
Intervention: GNN + OPS
Number of subjects: 300
Study 35212639 — intervention group
Group type: COMPARATOR
Intervention: GNN + COVID-19 ORR
Number of subjects: 300
Study 35212779 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenolanib (oral, once daily)
Number of subjects: 55
Study 35212779 — intervention group
Group type: EXPERIMENTAL
Intervention: Crenolanib with acid reducer cotreatment
Number of subjects: 55
Study 35212906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole (RIB + LET)
Number of subjects: 39
Study 35213039 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated endocrine therapy duration
Number of subjects: 0
Study 35213039 — intervention group
Group type: COMPARATOR
Intervention: Extended endocrine therapy
Number of subjects: 0
Study 35213495 — intervention group
Group type: EXPERIMENTAL
Intervention: StdPPM without fixation
Number of subjects: 25190
Study 35213495 — intervention group
Group type: EXPERIMENTAL
Intervention: StdPPM with metal tacks
Number of subjects: 25190
Study 35213495 — intervention group
Group type: EXPERIMENTAL
Intervention: StdPPM with fibrin glue
Number of subjects: 25190
Study 35213495 — intervention group
Group type: EXPERIMENTAL
Intervention: LWM with fibrin glue
Number of subjects: 25190
Study 35213495 — intervention group
Group type: EXPERIMENTAL
Intervention: LWM with metal tacks
Number of subjects: 25190
Study 35213495 — intervention group
Group type: EXPERIMENTAL
Intervention: LWM with absorbable tacks
Number of subjects: 25190
Study 35213495 — intervention group
Group type: EXPERIMENTAL
Intervention: LWM without fixation
Number of subjects: 25190
Study 35213523 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless single-lead ECG monitoring
Number of subjects: 398
Study 35213523 — intervention group
Group type: COMPARATOR
Intervention: Peripheral oxygen saturation (Spo2) <85% for >5 minutes
Number of subjects: 398
Study 35213528 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal drusenoid deposits (SDD)
Number of subjects: 126
Study 35213528 — intervention group
Group type: COMPARATOR
Intervention: Non-SDD (drusen only)
Number of subjects: 126
Study 35213713 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity clinic group (overweight/obesity)
Number of subjects: 2154
Study 35213713 — intervention group
Group type: COMPARATOR
Intervention: Population-based group (normal weight)
Number of subjects: 2154
Study 35213728 — intervention group
Group type: EXPERIMENTAL
Intervention: Eumenorrheic women
Number of subjects: 38
Study 35213728 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive users
Number of subjects: 38
Study 35213728 — intervention group
Group type: EXPERIMENTAL
Intervention: All data pooled
Number of subjects: 38
Study 35213769 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran
Number of subjects: 23
Study 35214767 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine
Number of subjects: 0
Study 35216589 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal Component Regression (PCR) models
Number of subjects: 388
Study 35216589 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian Kernel Machine Regression (BKMR) models
Number of subjects: 388
Study 35216589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches (PCR and BKMR)
Number of subjects: 388
Study 35216638 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based moderate-to-vigorous intensity exercise intervention (one aerobic exercise session at 80-90% VO2 max)
Number of subjects: 19
Study 35216638 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 35216832 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy
Number of subjects: 1095
Study 35216832 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 1095
Study 35216832 — intervention group
Group type: COMPARATOR
Intervention: Abdominal myomectomy
Number of subjects: 1095
Study 35216968 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy
Number of subjects: 218
Study 35216968 — intervention group
Group type: COMPARATOR
Intervention: Ovarian cancer screening (Control)
Number of subjects: 218
Study 35217573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 35217576 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based tumor mutational burden (bTMB) using a TMB panel of 1.1 Mb
Number of subjects: 185
Study 35217576 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based tumor mutational burden (bTMB)
Number of subjects: 185
Study 35217576 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based tumor mutational burden (bTMB) in stage IV samples with at least 20 ng of cfDNA input
Number of subjects: 185
Study 35217576 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized bTMB panel to a subset of 577 kb
Number of subjects: 185
Study 35218024 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network predicted rectal dose for patients with rectal spacer insertion
Number of subjects: 44
Study 35218324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 72 mg
Number of subjects: 397
Study 35218324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab 240 mg
Number of subjects: 397
Study 35218324 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 397
Study 35218324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 397
Study 35218366 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID patients
Number of subjects: 2086
Study 35218366 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID patients
Number of subjects: 2086
Study 35218665 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Sleep Restriction (CSR)
Number of subjects: 9
Study 35218665 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery Sleep
Number of subjects: 9
Study 35219065 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC206
Number of subjects: 0
Study 35219300 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemo-radiotherapy (pre-CRT)
Number of subjects: 222
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (stunting prevalence)
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (stunting prevalence)
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (wasting prevalence)
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (wasting prevalence)
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Untimely initiation of breastfeeding (Boys)
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Untimely initiation of breastfeeding (Girls)
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Untimely introduction to complementary food
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low consumption of legumes/nuts
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low egg consumption (Girls)
Number of subjects: 2036
Study 35219315 — intervention group
Group type: EXPERIMENTAL
Intervention: Region of residence and age of the mother
Number of subjects: 2036
Study 35219622 — intervention group
Group type: EXPERIMENTAL
Intervention: NiTiDES stent (Alvimedica)
Number of subjects: 100
Study 35219724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal LNPCPs
Number of subjects: 3405
Study 35220448 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO
Number of subjects: 1726
Study 35220448 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO, choline, and carnitine above the median
Number of subjects: 1726
Study 35220460 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative anaemia
Number of subjects: 9081
Study 35220658 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Number of subjects: 384
Study 35220665 — intervention group
Group type: EXPERIMENTAL
Intervention: Socioeconomic constraints (measured by Federal Poverty Level, receipt of public assistance, difficulty paying for housing, food, and other necessities)
Number of subjects: 2581
Study 35220665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual wellbeing measures (sexual functioning and satisfaction, frequency of orgasm, current sex-life rating)
Number of subjects: 2581
Study 35220688 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD patients (n=47)
Number of subjects: 94
Study 35220688 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (age- and sex-matched control group, n=47)
Number of subjects: 94
Study 35221224 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body insulin clearance
Number of subjects: 44
Study 35221224 — intervention group
Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR)
Number of subjects: 44
Study 35221224 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective renal plasma flow (ERPF)
Number of subjects: 44
Study 35221224 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin sensitivity (M value)
Number of subjects: 44
Study 35221224 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass
Number of subjects: 44
Study 35221650 — intervention group
Group type: COMPARATOR
Intervention: Serratus plane block (SPB) alone
Number of subjects: 60
Study 35221650 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of pectoral type 1 (PECS I) and serratus plane block (SPB)
Number of subjects: 60
Study 35221687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 489
Study 35221687 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 489
Study 35221687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 35221928 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterotopic Ossification treatment, specific details not available
Number of subjects: 0
Study 35222036 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR2285, a small-molecule Factor XIa inhibitor
Number of subjects: 0
Study 35222057 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID)
Number of subjects: 180
Study 35222057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient phenotyping in HFpEF
Number of subjects: 180
Study 35222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Visceral adiposity (measured via MRI)
Number of subjects: 33
Study 35222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory biomarkers (IL-6, TNF-α, CRP)
Number of subjects: 33
Study 35222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels
Number of subjects: 33
Study 35222077 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate synthase (CS) activity
Number of subjects: 33
Study 35222195 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 160
Study 35222195 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful self-compassion meditation
Number of subjects: 160
Study 35222195 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-induced cognitive trance (SICT)
Number of subjects: 160
Study 35222195 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 160
Study 35222248 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT after IV alteplase (combination-therapy group)
Number of subjects: 0
Study 35222248 — intervention group
Group type: COMPARATOR
Intervention: EVT alone (EVT-alone group)
Number of subjects: 0
Study 35222429 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 516
Study 35222429 — intervention group
Group type: COMPARATOR
Intervention: Non-COVID-19 controls
Number of subjects: 516
Study 35222719 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil treatment (Group A, n=52)
Number of subjects: 104
Study 35222719 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil plus hyperbaric oxygen (HBO) treatment (Group B, n=52)
Number of subjects: 104
Study 35222735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction training (MBSR)
Number of subjects: 0
Study 35222735 — intervention group
Group type: EXPERIMENTAL
Intervention: FibroQoL
Number of subjects: 0
Study 35222735 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0